Almanack Investment Partners LLC. Purchases Shares of 1,434 Boston Scientific Co. (NYSE:BSX)

Almanack Investment Partners LLC. purchased a new stake in Boston Scientific Co. (NYSE:BSX – Get Rating) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 1,434 shares of the medical equipment provider’s stock, valued at approximately $56,000.

Other institutional investors also recently bought and sold shares of the company. CoreCap Advisors LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $27,000. Acadian Asset Management LLC acquired a new position in Boston Scientific in the 1st quarter valued at $35,000. Massmutual Trust Co. FSB ADV raised its holdings in Boston Scientific by 68.4% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 1,000 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 406 shares during the last quarter. Adirondack Trust Co. grew its stake in shares of Boston Scientific by 126.0% during the 3rd quarter. Adirondack Trust Co. now owns 1,130 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 630 shares during the period. Finally, Washington Trust Advisors Inc. grew its stake in shares of Boston Scientific by 192.5% during the 3rd quarter. Washington Trust Advisors Inc. now owns 1,284 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 845 shares during the period. 90.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Wendy Carruthers sold 7,500 shares of the stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $46.62, for a total transaction of $349,650.00. Following the sale, the executive vice president now owns 87,413 shares in the company, valued at $4,075,194.06. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CAO Jonathan Monson sold 5,000 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $46.66, for a total transaction of $233,300.00. Following the sale, the chief accounting officer now owns 34,868 shares in the company, valued at $1,626,940.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Wendy Carruthers sold 7,500 shares of the stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $46.62, for a total transaction of $349,650.00. Following the sale, the executive vice president now owns 87,413 shares in the company, valued at approximately $4,075,194.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 122,682 shares of company stock worth $5,782,324. 0.66% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BSX. Mizuho began coverage on shares of Boston Scientific in a research note on Thursday, December 22nd. They set a “neutral” rating and a $52.00 price objective for the company. Barclays boosted their price objective on shares of Boston Scientific from $49.00 to $53.00 in a research note on Wednesday, January 4th. Citigroup began coverage on shares of Boston Scientific in a research note on Tuesday, December 20th. They set a “buy” rating and a $54.00 price objective for the company. Raymond James boosted their price objective on shares of Boston Scientific from $54.00 to $56.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 2nd. Finally, TheStreet cut shares of Boston Scientific from a “b-” rating to a “c” rating in a research report on Monday, November 28th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $51.50.

Boston Scientific Stock Performance

NYSE:BSX opened at $48.31 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.51 and a quick ratio of 1.02. The firm has a 50-day moving average of $46.75 and a two-hundred day moving average of $44.10. The stock has a market cap of $69.31 billion, a P/E ratio of 107.36, a PEG ratio of 2.19 and a beta of 0.79. Boston Scientific Co. has a 1-year low of $34.98 and a 1-year high of $48.87.

Boston Scientific (NYSE:BSX – Get Rating) last issued its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The company had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.24 billion. Boston Scientific had a net margin of 5.50% and a return on equity of 14.29%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.45 EPS. On average, research analysts expect that Boston Scientific Co. will post 1.9 earnings per share for the current fiscal year.

Boston Scientific Profile

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.